Current issue
About the Journal
Scientific Council
Editorial Board
Regulatory and archival policy
Code of publishing ethics
Publisher
Information about the processing of personal data in relation to cookies and newsletter subscription
Archive
For Authors
For Reviewers
Contact
Reviewers
Annals reviewers in 2022
Annals reviewers in 2021
Annals reviewers in 2020
Annals reviewers in 2019
Annals reviewers in 2018
Annals reviewers in 2017
Annals reviewers in 2016
Annals reviewers in 2015
Annals reviewers in 2014
Annals reviewers in 2013
Annals reviewers in 2012
Links
Sklep Wydawnictwa SUM
Biblioteka Główna SUM
Śląski Uniwersytet Medyczny w Katowicach
Privacy policy
Accessibility statement
Sentinel lymph node (SLN) identification in breast cancer patients,
using SentiMag® ferromagnetic method. Assessment of usefulness
and limitations in group of our own patients
1
Klinika Chirurgii Onkologicznej, Wydział Lekarski z Oddziałem Lekarsko-Dentystycznym w Zabrzu,
Śląski Uniwersytet Medyczny w Katowicach
2
Klinika Onkologii Klinicznej, Wydział Lekarski z Oddziałem Lekarsko-Dentystycznym w Zabrzu,
Śląski Uniwersytet Medyczny w Katowicach
3
Katedra i Klinika Chirurgii Ogólnej, Naczyniowej i Transplantacyjnej, Wydział Lekarski w Katowicach,
Śląski Uniwersytet Medyczny w Katowicach
Corresponding author
Andrzej Lorek
Klinika Chirurgii Onkologicznej, Wydział Lekarski z Oddziałem Lekarsko-Dentystycznym w Zabrzu, Śląski Uniwersytet Medyczny w Katowicach, ul. Ceglana 35, 40-514 Katowice, tel. +48 32 358 13 15
Klinika Chirurgii Onkologicznej, Wydział Lekarski z Oddziałem Lekarsko-Dentystycznym w Zabrzu, Śląski Uniwersytet Medyczny w Katowicach, ul. Ceglana 35, 40-514 Katowice, tel. +48 32 358 13 15
Ann. Acad. Med. Siles. 2016;70:236–241
KEYWORDS
Sentinel lymph node biopsybreast cancersuperparamagnetic particles of iron oxidebreast density according to the American College of Radiology (ACR)
TOPICS
ABSTRACT
Objective:
The paper aims to assess SLN signal intensity, depending on: breast density according to ACR (American College of Radiology), age, the presence of scars and the time from tracer administration.
Material and methods:
The study encompassed 161 SLN biopsies. The study group included 14 patients with scars.
Results:
Analysing the influence of ACR-based breast density and the time from tracer administration on the SLN signal intensity, a statistically positive correlation was found between signal intensity and the time from tracer administration in patients with ACR levels 1 and 2. In the ACR level 3 and 4 groups, no significant correlation was found. SLN signal intensity in relation to the patients’ age indicated a statistically significant negative correlation of SLN signal intensity in the entire group and in ACR 1. The analysis of 14 patients with scars demonstrated a statistically significant lower SLN signal intensity.
Conclusions:
It was found that the time from Sienna+® administration affects SLN signal intensity in relation to ACR-based breast density types 1 and 2. No such correlation was observed in density types 3 and 4. Elderly patients, especially with ACR-based breast density types 1 and 2, are more likely to present lower values of SLN impulses. Patients who had earlier surgical interventions within the upper external quadrants are more likely to present lower values of SLN impulses.
The paper aims to assess SLN signal intensity, depending on: breast density according to ACR (American College of Radiology), age, the presence of scars and the time from tracer administration.
Material and methods:
The study encompassed 161 SLN biopsies. The study group included 14 patients with scars.
Results:
Analysing the influence of ACR-based breast density and the time from tracer administration on the SLN signal intensity, a statistically positive correlation was found between signal intensity and the time from tracer administration in patients with ACR levels 1 and 2. In the ACR level 3 and 4 groups, no significant correlation was found. SLN signal intensity in relation to the patients’ age indicated a statistically significant negative correlation of SLN signal intensity in the entire group and in ACR 1. The analysis of 14 patients with scars demonstrated a statistically significant lower SLN signal intensity.
Conclusions:
It was found that the time from Sienna+® administration affects SLN signal intensity in relation to ACR-based breast density types 1 and 2. No such correlation was observed in density types 3 and 4. Elderly patients, especially with ACR-based breast density types 1 and 2, are more likely to present lower values of SLN impulses. Patients who had earlier surgical interventions within the upper external quadrants are more likely to present lower values of SLN impulses.
REFERENCES (20)
1.
Schwartz G., Giuliano A., Veronesi U. Preceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19–22, 2001, Philadelphia, Pennsylvania. Cancer 2002; 94: 2542–2551.
2.
Douek M., Klaase J., Monypenny I., Kothari A., Zechmeister K., Brown D., Wyld L., Drew P., Garmo H., Agbaje O., Pankhurst Q., Anninga B., Grootendorst M., Ten Haken B., Hall-Craggs M.A., Purushotham A., Pinder S. Sentinel node biopsy using a magnetic tracer versus standard technique: the SentiMAG Multicentre Trial. Ann. Surg. Oncol. 2014; 21(4): 1237–1245.
3.
Thill M., Kurylcio A., Welter R., van Haasteren V., Grosse B., Berclaz G., Polkowski W., Hauser N. Response to Barranger E., Ihrai T., response to the article by Thill et al.: "The Central-European SentiMagstudy: Sentinel lymph node biopsy with supermagnetic iron oxide (SPIO) vs. radioisotope". The Breast 2014; 23(2): 175–179. Breast 2014; 23(5): 692.
4.
Rubio I.T., Diaz-Botero S., Esgueva A., Rodriguez R., Cortadellas T., Cordoba O., Espinosa-Bravo M. The superparamagnetic iron oxide is equivalent to the Tc99 radiotracer method for identifying the sentinel lymph node in breast cancer. Eur. J. Surg. Oncol. 2015; 41(1): 46–51.
5.
Piñero-Madrona A., Torró-Richart J.A., de León-Carrillo J.M., de Castro-Parga G., Navarro-Cecilia J., Domínguez-Cunchillos F., Román-San-tamaría J.M., Fuster-Diana C., Pardo-García R. Superparamagnetic iron oxide as a tracer for sentinel node biopsy in breast cancer: a comparative non-inferiority study. Eur. J. Surg. Oncol. 2015; 41(8): 991–997.
6.
Pouw J.J., Grootendorst M.R., Bezooijen R., Klazen CA., De Bruin W.I., Klaase J.M., Hall-Craggs M.A., Douek M., Ten Haken B. Pre-operative sentinel lymph node localization in breast cancer with superparamagnetic iron oxide MRI: the SentiMAG Multicentre Trial imaging subprotocol. Br. J. Radiol. 2015; 88(1056): 20150634.
7.
Ghilli M., MD Carretta E., Di Filippo F., Battaglia C., Fustaino L., Galanou I., Di Filippo S., Rucci P., Fantini M.P., Roncella M. The super-paramagnetic iron oxide tracer: a valid alternative in sentinel node biopsy for breast cancer treatment. Eur. J. Cancer Care 2015; Sep 14: DOI: 10.1111/ecc.12385.
8.
Tafra L., Lannin D.R., Swanson M.S., Van Eyk J.J., Verbanac K.M., Chua A.N., Ng P.C., Edwards M.S., Halliday B.E., Henry C.A., Sommers L.M., Carman C.M., Molin M.R., Yurko J.E., Perry R.R., Williams R. Multicenter trial of sentinel node biopsy for breast cancer using both technetium sulfur colloid and isosulfan blue dye. Ann. Surg. 2001; 233: 51–59.
9.
Cox C.E., Dupont E., Whitehead G.F., Ebert M.D., Nguyen K., Peltz E.S., Peckham D., Cantor A. Age and body mass index may increase the chance of failure in sentinel lymph node biopsy for women with breast cancer. Breast J. 2002; 8(2): 88–91.
10.
Haut J., Jacob D., Laurent E., Rubinstein M., Rahier L. Preoperative localisation and analysis (preoperative and definitive) of the sentinel node in clinical and subclinical breast carcinoma. Presented at the Second International Sentinel Node Congress, December 1–4. Santa Monica 2000 (Abstract Book p. 54).
11.
Hughes M., Goffman T.G., Perry R.R., Laronga C. Obesity and lymphatic mapping with sentinel lymph node biopsy in breast cancer. Am. J. Surg. 2004; 187(1): 52–57.
12.
Sutton R., Kollias J., Prasad V., Chatterton B., Grantley Gill P. Sameday lymphoscintigraphy and sentinel node biopsy for early breast cancer. ANZ J. Surg. 2002; 72(8): 542–546.
13.
Bergkvist L., Frisell J., Liljegren G., Celebioglu F., Damm S., Thörn M. Multicentre study of detection and false-negative rates in sentinel node biopsy for breast cancer. Br. J. Surg. 2001; 88(12): 1644–1648.
14.
Lamichhane N., Shen K.W., Li C.L., Han Q.X., Zhang Y.J., Shao Z.M. Sentinel lymph node biopsy in breast cancer patients after overnight migration of radiolabelled sulphur colloid. Postgrad. Med. J. 2004; 80: 546–550.
15.
Schirrmeister H., Kotzerke J., Vogl F., Buck A., Czech N., Koretz K., Helm G., Kreienberg R., Kühn T. Prospective evaluation of factors influencing success rates of sentinel node biopsy in 814 breast cancer patients. Cancer Biother. Radiopharm. 2004; 19: 784–790.
16.
Yararbas U., Argon A.M., Yeniay L., Kapkac M. Problematic aspects of sentinel lymph node biopsy and its relation to previous excisional biopsy in breast cancer. Clin. Nucl. Med. 2009; 34(12): 854–858.
17.
Tafra L., Lannin D.R., Swanson M.S., Van Eyk J.J., Verbanac K.M., Chua A.N., Ng P.C., Edwards M.S., Halliday B.E., Henry C.A., Sommers L.M., Carman C.M., Molin M.R., Yurko J.E., Perry R.R., Williams R. Multicenter trial of sentinel node biopsy for breast cancer usunig both technetium sulfur colloid and isosulfan blue dye. Ann. Surg. 2001; 233: 51–59.
18.
Luini A., Galimberti V., Gatti G., Arnone P., Vento A.R., Trifirò G., Viale G., Rotmensz N., Fernandez J.R., Gilardi D., Paganelli G. The sentinel node biopsy after previous breast surgery: preliminary results on 543 patients treated at the European Institute of Oncology. Breast Cancer Res. Treat. 2005; 89: 159–163.
19.
Celebioglu F., Frisell J., Danielsson R., Bergkvist L. Sentinel node biopsy in non-palpable breast cancer and in patients with a previous diagnostic excision. Eur. J. Surg. Oncol. 2007; 33: 276–280.
20.
Haigh P.I., Hansen N.M., Qi K., Giuliano A.E. Biopsy method and excision volume do not affect success rate of subsequent sentinel lymph node dissection in breast cancer. Ann. Surg. Oncol. 2000; 7: 21–27.
Share
RELATED ARTICLE
The Medical University of Silesia in Katowice, as the Operator of the annales.sum.edu.pl website, processes personal data collected when visiting the website. The function of obtaining information about Users and their behavior is carried out by voluntarily entered information in forms, saving cookies in end devices, as well as by collecting web server logs, which are in the possession of the website Operator. Data, including cookies, are used to provide services in accordance with the Privacy policy.
You can consent to the processing of data for these purposes, refuse consent or access more detailed information.
You can consent to the processing of data for these purposes, refuse consent or access more detailed information.